Pharvaris N.V. (PHVS)
Chart Events
Performance Outlook
| Previous Close | 25.42 |
| Open | 26.68 |
| Bid | 25.00 x 4000 |
| Ask | 25.59 x 1400 |
| Day's Range | 25.12 - 26.68 |
| 52 Week Range | 6.02 - 29.80 |
| Volume | |
| Avg. Volume | 86,528 |
| Market Cap | 1.324B |
| Beta (5Y Monthly) | -3.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.27 |
| Earnings Date | Nov 02, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.32 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PHVS
Related Research
- Pharvaris N.V.Daily – Vickers Top Buyers & Sellers for 06/05/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 months agoArgus Research
Simply Wall St.Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last week
Key Insights Significant control over Pharvaris by private equity firms implies that the general public has more power...
GlobeNewswirePharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network (GA²LEN) Urticaria Centers of Reference and Excellence (UCARE) Conference, being held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, B
ZacksPharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.
